Inhibikase Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Inhibikase Therapeutics
IKT Stock  USD 2.76  0.16  5.48%   
Inhibikase Therapeutics financial statements provide useful quarterly and yearly information to potential Inhibikase Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Inhibikase Therapeutics financial statements helps investors assess Inhibikase Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Inhibikase Therapeutics' valuation are summarized below:
Gross Profit
-8.3 M
Market Capitalization
196.2 M
Enterprise Value Revenue
2.748
Revenue
79.6 K
Earnings Share
(3.12)
There are currently one hundred twenty fundamental trends for Inhibikase Therapeutics that can be evaluated and compared over time across competitors. All traders should confirm Inhibikase Therapeutics' regular fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 7.4 M in 2024. Enterprise Value is likely to gain to about (1.9 M) in 2024

Inhibikase Therapeutics Total Revenue

247,475

Check Inhibikase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibikase Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.9 K, Net Interest Income of 935.8 K or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 24.7, Dividend Yield of 0.0 or PTB Ratio of 0.65. Inhibikase financial statements analysis is a perfect complement when working with Inhibikase Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Inhibikase Therapeutics Correlation against competitors.
For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

Inhibikase Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities3.7 M3.4 M2.7 M
Slightly volatile
Accounts Payable1 M646.8 K730.1 K
Slightly volatile
Other Assets1.091.15313.5 K
Pretty Stable
Total Current Assets13.4 M14.2 M7.4 M
Slightly volatile
Common Stock5.9 K6.2 K10.7 K
Slightly volatile
Other Current Liabilities1.9 M2.3 M921.5 K
Slightly volatile
Total Assets18.3 M14.5 M9.4 M
Slightly volatile
Short and Long Term Debt Total393.9 K622 K294.2 K
Slightly volatile
Current Deferred Revenue1.5 M2.7 M994.3 K
Slightly volatile
Cash13.1 M9.2 M5.8 M
Slightly volatile
Non Currrent Assets Other9.2 M18.2 M6 M
Slightly volatile
Cash And Short Term Investments16.8 M13.3 M7.4 M
Slightly volatile
Common Stock Total Equity8.599.055.5 K
Slightly volatile
Common Stock Shares Outstanding3.2 M5.3 M2.1 M
Slightly volatile
Liabilities And Stockholders Equity18.3 M14.5 M9.4 M
Slightly volatile
Non Current Liabilities Total85.6 K90.1 K1.1 M
Slightly volatile
Other Current Assets729.2 K959 K526.6 K
Slightly volatile
Other Stockholder Equity46.4 M77.9 M23 M
Slightly volatile
Total Liabilities3.3 M3.5 M3.8 M
Pretty Stable
Deferred Long Term Liabilities2.5 K2.6 K958 K
Slightly volatile
Short and Long Term Debt124.7 K224 K206.1 K
Slightly volatile
Capital Stock5.9 K6.2 K10.3 K
Slightly volatile
Short Term Debt558.5 K531.9 K248.6 K
Slightly volatile
Long Term Debt303.5 K317.9 K280.3 K
Slightly volatile
Inventory858.8 K1.3 M303 K
Slightly volatile

Inhibikase Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.3 M6.7 M3.6 M
Slightly volatile
Total Revenue247.5 K260.5 K2.8 M
Slightly volatile
Other Operating Expenses11.7 M20.4 M6.2 M
Slightly volatile
Research Development8.1 M13.6 M5.4 M
Slightly volatile
Total Operating Expenses9.2 M6.7 M5.1 M
Slightly volatile
Depreciation And Amortization168.5 K177.4 K5 M
Slightly volatile
Cost Of Revenue14.3 M13.6 M4.4 M
Slightly volatile
Interest Income531.1 K891.2 K159.3 K
Slightly volatile

Inhibikase Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cashflows From Investing Activities69.7 K78.4 K85.4 K
Slightly volatile
Other Cashflows From Investing Activities69.7 K78.4 K85.4 K
Slightly volatile
Change To Netincome1.6 M2.6 M1.1 M
Slightly volatile
End Period Cash Flow11.2 M9.2 M5.5 M
Slightly volatile
Stock Based Compensation685.7 K500.1 K731.1 K
Pretty Stable
Begin Period Cash Flow11.4 M7.2 M4.9 M
Slightly volatile
Other Non Cash Items30 K31.5 K744 K
Pretty Stable
Issuance Of Capital Stock13.6 M8.5 M6.5 M
Slightly volatile
Dividends Paid62.1 K69.9 K76.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio24.726.000165.3016
Slightly volatile
Days Sales Outstanding11110641.7174
Slightly volatile
Average Payables822.7 K1 M819.7 K
Slightly volatile
Stock Based Compensation To Revenue2.021.920.853
Slightly volatile
Capex To Depreciation0.07620.080331.3686
Slightly volatile
Inventory Turnover0.00660.006984.9292
Slightly volatile
Days Of Inventory On Hand57.3 K54.6 K11.5 K
Slightly volatile
Payables Turnover22.1121.0565.2782
Slightly volatile
Sales General And Administrative To Revenue0.50.560.6103
Slightly volatile
Research And Ddevelopement To Revenue54.8952.277714.6507
Slightly volatile
Capex To Revenue0.05190.05471.715
Slightly volatile
Cash Per Share3.012.48492.2071
Slightly volatile
Days Payables Outstanding16.4717.33474.3 K
Slightly volatile
Current Ratio2.494.13281.8441
Slightly volatile
Receivables Turnover3.383.5614.3792
Pretty Stable
Graham Number11.1212.85529.5019
Slightly volatile
Capex Per Share0.00250.00270.0505
Slightly volatile
Average Receivables21.8 K22.9 K223.5 K
Slightly volatile
Revenue Per Share0.04640.04880.7767
Pretty Stable
Interest Debt Per Share0.0680.07160.1972
Slightly volatile
Debt To Assets0.0250.02631.7122
Pretty Stable
Operating Cycle57.5 K54.7 K11.6 K
Slightly volatile
Days Of Payables Outstanding16.4717.33474.3 K
Slightly volatile
Ebt Per Ebit1.110.94721.0224
Very volatile
Quick Ratio2.464.13281.8202
Slightly volatile
Net Income Per E B T1.11.141.0191
Slightly volatile
Cash Ratio1.782.66541.3047
Slightly volatile
Days Of Inventory Outstanding57.3 K54.6 K11.5 K
Slightly volatile
Days Of Sales Outstanding11110641.7174
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00081.0195
Slightly volatile
Fixed Asset Turnover0.930.88130.31
Slightly volatile
Debt Ratio0.0250.02631.7122
Pretty Stable
Price Sales Ratio24.726.000165.3016
Slightly volatile
Asset Turnover0.01710.0185.3146
Pretty Stable

Inhibikase Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap7.4 M7.8 M62.8 M
Slightly volatile

Inhibikase Fundamental Market Drivers

Cash And Short Term Investments13.3 M

Inhibikase Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Inhibikase Therapeutics Financial Statements

Inhibikase Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Inhibikase Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Inhibikase Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Inhibikase Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.7 M1.5 M
Total Revenue260.5 K247.5 K
Cost Of Revenue13.6 M14.3 M
Stock Based Compensation To Revenue 1.92  2.02 
Sales General And Administrative To Revenue 0.56  0.50 
Research And Ddevelopement To Revenue 52.28  54.89 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(77.12)(73.26)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY